Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections (ACCUTE)

What is the purpose of this trial?

The purpose of this study is to determine whether AB103 is safe and effective in the treatment of patients with necrotizing soft tissue infections receiving standard of care therapy.

Participation Guidelines

Ages: 12 years and older

Gender: Both

Atox Bio

Start Date: 10/26/2015

End Date: 09/30/2017

Last Updated: 06/22/2018

Study HIC#: 1507016217

Get Involved

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email or call 1-877-978-8348.

Trial Image


Adrian Maung

Principal Investigator